T. Rowe Price Associates’s Abiomed Inc ABMD Stock Holding History

T. Rowe Price Associates’s Portfolio ABMD Stock Details ABMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-130,875	Closed	-$32.2M	–	3027
2022 Q3	$32.2M	Sell	130,875 -1,167	-0.9%	-$315K	0.01%	769
2022 Q2	$32.7M	Sell	132,042 -4,492	-3%	-$1.21M	﹤0.01%	1016
2022 Q1	$45.2M	Sell	136,534 -4,490	-3%	-$1.38M	﹤0.01%	1001
2021 Q4	$50.7M	Sell	141,024 -442	-0.3%	-$149K	﹤0.01%	1003
2021 Q3	$46M	Sell	141,466 -1,200	-0.8%	-$407K	﹤0.01%	1048
2021 Q2	$44.5M	Buy	142,666 +2,476	+2%	+$760K	﹤0.01%	1066
2021 Q1	$44.7M	Sell	140,190 -188	-0.1%	-$60.2K	﹤0.01%	1046
2020 Q4	$45.5M	Sell	140,378 -2,929	-2%	-$810K	﹤0.01%	994
2020 Q3	$39.7M	Buy	143,307 +140	+0.1%	+$40.3K	﹤0.01%	947
2020 Q2	$34.6M	Sell	143,167 -25,971	-15%	-$5.21M	﹤0.01%	977
2020 Q1	$24.6M	Sell	169,138 -718,153	-81%	-$119M	﹤0.01%	1001
2019 Q4	$151M	Buy	887,291 +118,696	+15%	+$22M	0.02%	549
2019 Q3	$137M	Buy	768,595 +477,638	+164%	+$103M	0.02%	531
2019 Q2	$75.8M	Buy	290,957 +54,709	+23%	+$14.5M	0.01%	730
2019 Q1	$67.5M	Buy	236,248 +20,034	+9%	+$6.66M	0.01%	755
2018 Q4	$70.3M	Buy	216,214 +139,681	+183%	+$48.5M	0.01%	696
2018 Q3	$34.4M	Buy	76,533 +4,903	+7%	+$1.93M	0.01%	1045
2018 Q2	$29.3M	Buy	71,630 +56,040	+359%	+$20.3M	﹤0.01%	1072
2018 Q1	$4.54M	Buy	15,590 +240	+2%	+$60.8K	﹤0.01%	1442
2017 Q4	$2.88M	Sell	15,350 -9,744	-39%	-$1.82M	﹤0.01%	1505
2017 Q3	$4.23M	Buy	25,094 +7,210	+40%	+$1.09M	﹤0.01%	1459
2017 Q2	$2.56M	Sell	17,884 -2,022	-10%	-$272K	﹤0.01%	1507
2017 Q1	$2.49M	Buy	19,906 +2,881	+17%	+$334K	﹤0.01%	1526
2016 Q4	$1.92M	Buy	17,025 +2,806	+20%	+$325K	﹤0.01%	1574
2016 Q3	$1.83M	Buy	14,219 +7	+0%	+$838	﹤0.01%	1558
2016 Q2	$1.55M	Sell	14,212 -1,588	-10%	-$158K	﹤0.01%	1585
2016 Q1	$1.5M	Buy	15,800 +2,190	+16%	+$185K	﹤0.01%	1596
2015 Q4	$1.23M	Buy	13,610 +1,610	+13%	+$137K	﹤0.01%	1635
2015 Q3	$1.11M	Sell	12,000 -171,650	-93%	-$15.1M	﹤0.01%	1674
2015 Q2	$12.1M	Buy	183,650 +170,350	+1,281%	+$11.3M	﹤0.01%	1298
2015 Q1	$952K	Buy	13,300 +3,300	+33%	+$179K	﹤0.01%	1754
2014 Q4	$381K	Hold	10,000	–	–	﹤0.01%	2070
2014 Q3	$248K	Hold	10,000	–	–	﹤0.01%	2240
2014 Q2	$251K	Hold	10,000	–	–	﹤0.01%	2258
2014 Q1	$260K	Buy	+10,000	New	+$277K	﹤0.01%	2224
2013 Q4	–	Sell	-12,300	Closed	-$235K	–	2520
2013 Q3	$235K	Hold	12,300	–	–	﹤0.01%	2209
2013 Q2	$265K	Buy	+12,300	New	+$247K	﹤0.01%	2119

Other funds holding ABMD

TRSOTSOK

Teachers Retirement System of the State of Kentucky Frankfort, Kentucky $12.9B AUM 31.03% 1-Year Est. Return

BTI

Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

Rockefeller Capital Management New York $56.4B AUM 24.96% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Avion Wealth The Woodlands, Texas $537M AUM 18.24% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

T. Rowe Price Associates's ABMD Position: Q4 2022 in Review

T. Rowe Price Associates sold out of Abiomed Inc (ABMD) in Q4 2022, closing a stake of 130,875 shares — an estimated $32.2M sold.

T. Rowe Price Associates first reported a position in ABMD in Q2 2013 and held it in 37 quarters. The position peaked at $151M in Q4 2019. 8 funds tracked by Wall St. Rank hold ABMD as of Q4 2022.

T. Rowe Price Associates reported no remaining Abiomed Inc position as of Q4 2022 after selling out during the quarter.
T. Rowe Price Associates sold 130,875 Abiomed Inc shares in Q4 2022, an estimated $32.2M.
T. Rowe Price Associates first reported a position in Abiomed Inc in Q2 2013 and held it in 37 quarters.
T. Rowe Price Associates's Abiomed Inc position peaked at $151M in Q4 2019.
8 funds tracked by Wall St. Rank held Abiomed Inc as of Q4 2022.

Based on T. Rowe Price Associates's 13F filing for Q4 2022, filed 14 Feb 2023.